Johnson & Johnson (JNJ) has announced additional insights from the Phase 2 DAHLIAS study, which assesses the effects of Nipocalimab on individuals with primary Sjogren's disease, a chronic autoimmune disorder. The study results indicated notable improvements in significant disease activity metrics, with IgG levels reduced by more than 77 percent after treatment.
The research achieved its primary goal, with participants showing progress in the ClinESSDAI score at the 24-week mark. Furthermore, key secondary goals were accomplished, including a decrease in overall disease activity and across multiple organ systems. There were also enhancements in physician evaluations and composite Sjogren's disease assessment tools, according to the company.
At present, Johnson & Johnson's shares are trading at $151.21, representing a 1.34 percent decline on the New York Stock Exchange.
